<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963676</url>
  </required_header>
  <id_info>
    <org_study_id>13-2995</org_study_id>
    <nct_id>NCT01963676</nct_id>
  </id_info>
  <brief_title>Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia</brief_title>
  <official_title>Clinical Trial to Assess Transcranial Current Stimulation as a Treatment for Medication Refractory Auditory Hallucinations in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the effect of non-invasive transcranial current stimulation on auditory
      hallucinations in patients with schizophrenia. Normal neuronal activity is perturbed in
      schizophrenia, so selective targeting of this abnormal activity could serve as a treatment
      for schizophrenia and alleviate symptoms caused by abnormal neuronal activity, such as
      auditory hallucinations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM 1: To evaluate the effect of transcranial direct current stimulation (tDCS) (2mA for
      20min on five consecutive days) on auditory hallucinations in schizophrenia patients using
      the change in ratings on the Auditory Hallucination Rating Scale (AHRS) by patients before
      and after stimulation. We hypothesize that tDCS will modulate the abnormal neuronal activity
      found in schizophrenic patients and thereby decrease their auditory hallucinations when
      measured after stimulation.

      AIM 2: To evaluate the long term effects of tDCS by having patients give a rating on the AHRS
      after one month has passed since stimulation and comparing this value to their baseline score
      and their score immediately after stimulation. We hypothesize that there will remain a
      significant reduction in auditory hallucination score in participants who received tDCS at
      one month.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Auditory Hallucination Rating Scale (AHRS)Score From Baseline to Day 5</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Examining AHRS total score after 5 days of stimulation compared to baseline assessment total.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of Decrease in AHRS Score Over Time</measure>
    <time_frame>Day 5, One month</time_frame>
    <description>We will re-assess patients one month after the completion of stimulation to evaluate whether their change from baseline to day 5 score on the AHRS persisted over time, namely 30 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Auditory Hallucinations</condition>
  <arm_group>
    <arm_group_label>transcranial direct current stimulation (tDCS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13 subjects total. 2mA stimulation for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <arm_group_label>transcranial direct current stimulation (tDCS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham stimulation</intervention_name>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic and Statistical Manual IV (DSM-IV) diagnosis of schizophrenia, any subtype,
             or schizoaffective disorder, with refractory auditory hallucinations. Duration of
             illness &gt;1 year.

          -  18-99 years old.

          -  Clinically stable for at least 12 weeks, i.e. not requiring hospitalization or a
             change in level of care .

          -  On current antipsychotic doses for approximately 4 weeks or more.

          -  Capacity to understand all relevant risks and potential benefits of the study
             (informed consent) OR has a legal guardian who can complete consent forms on the
             patients behalf

          -  Right handed

        Exclusion Criteria:

          -  Subjects with a DSM-IV diagnosis of alcohol or substance abuse (other than nicotine)
             within the last month or a DSM-IV diagnosis of alcohol or substance dependence (other
             than nicotine) within the last 6 months.

          -  History of significant head injury/trauma, as defined by loss of consciousness for
             more than 1 hour, or recurring seizures, or requiring later cognitive rehabilitation
             or causing cognitive sequelae.

          -  Prior brain surgery.

          -  Any brain devices/implants, including cochlear implants and aneurysm clips.

          -  Co-morbid neurological condition (i.e. seizure disorder, brain tumor).

          -  Medical or neurological illness (unstable cardiac disease AIDS, malignancy, liver or
             renal impairment) or treatment for a medical disorder that could interfere with study
             participation.

          -  Non English speakers.

          -  Pregnancy, nursing, or if female and fertile, unwilling to use appropriate birth
             control measures during study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Frohlich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina at Chapel Hill, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill, Outpatient STEP Clinic</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Wake STEP Clinic</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, Saoud M, Mechri A, Poulet E. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012 Jul;169(7):719-24. doi: 10.1176/appi.ajp.2012.11071091. Erratum in: Am J Psychiatry. 2012 Dec 1;169(12):1321.</citation>
    <PMID>22581236</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2013</study_first_submitted>
  <study_first_submitted_qc>October 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <results_first_submitted>December 10, 2015</results_first_submitted>
  <results_first_submitted_qc>January 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2016</results_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Flavio Frohlich, PhD</investigator_full_name>
    <investigator_title>Assistant Professor, Departments of Psychiatry, Cell Biology and Physiology, and Biomedical Engineering</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>auditory hallucinations</keyword>
  <keyword>transcranial stimulation</keyword>
  <keyword>tDCS</keyword>
  <keyword>tACS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Hallucinations</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited through medical providers. Providers knew inclusion/exclusion criteria and discussed the study with patients during their regular appointments. Interested participants contacted the study team. Participants recruited from the STEP clinic (Chapel Hill and Raleigh), and the Burlington ACT team. Recruitment between 4/14 and 9/14.</recruitment_details>
      <pre_assignment_details>Subjects randomly assigned to one of two groups, transcranial direct stimulation (tDCS) group or active sham group. tDCS group, direct current was delivered during awake, resting state for 20minutes on 5 consecutive days. Sham stimulation was delivered for an equal period of time and number of sessions. 27 subjects signed consent, 1 withdrew.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Transcranial Direct Current Stimulation (tDCS)</title>
          <description>13 subjects total. 2mA stimulation for 20 minutes.
tDCS</description>
        </group>
        <group group_id="P2">
          <title>Sham Stimulation</title>
          <description>13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
Sham stimulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Based on our randomized block design model, a block size of 10 (subjects, 20 total), 2 levels of (within-factors) TREATMENT and TIME each and a residual standard deviation of 14 (Brunelin et al., 2012), the power of our study is estimated to be 0.85 at the significant level alpha=0.05 and the difference of percentage change in 5 days of 15.</population>
      <group_list>
        <group group_id="B1">
          <title>Transcranial Direct Current Stimulation (tDCS)</title>
          <description>13 subjects total. 2mA stimulation for 20 minutes.
tDCS</description>
        </group>
        <group group_id="B2">
          <title>Sham Stimulation</title>
          <description>13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
Sham stimulation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.38" spread="12.64"/>
                    <measurement group_id="B2" value="40.00" spread="10.74"/>
                    <measurement group_id="B3" value="41.69" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Auditory Hallucination Rating Scale</title>
          <description>Remission according to AHRS: AHRS score equal to 0. AHRS: standardized, clinician-administered rating scale; assesses 11 aspects characteristically associated with auditory hallucination. Individual items are scored on a 5 point (0 to 4), with 0=none/absent and 4=most severe. Total score: 0 to 44; higher score indicates more severe auditory hallucination symptoms. Scores for each question summed up for total score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.00" spread="6.90"/>
                    <measurement group_id="B2" value="26.69" spread="6.30"/>
                    <measurement group_id="B3" value="26.85" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive and Negative Syndrome Scale</title>
          <description>Remission according to PANSS: PANSS score equal to 30. PANSS: standardized, clinician-administered rating scale. 3 subscales; Positive Symptom scale: 7 items, Negative Symptom scale: 7 items, General Symptom scale: 16 items. Each item in each subscale are scored on a 7 point (1 to 7) scale, with 1=none/absent and 7=most severe. Total score for Positive Scale: 7 to 49. Total score for Negative Scale: 7 to 49. Total score for general scale: 16 to 112. Total score for PANSS: 30 to 210; higher score indicates more severe symptoms. The PANSS total score by adding the sums of each subscale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.15" spread="12.90"/>
                    <measurement group_id="B2" value="66.92" spread="17.17"/>
                    <measurement group_id="B3" value="70.04" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Auditory Hallucination Rating Scale (AHRS)Score From Baseline to Day 5</title>
        <description>Examining AHRS total score after 5 days of stimulation compared to baseline assessment total.</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Per protocol; All participants who completed every session of the study from the initial session through the one month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Direct Current Stimulation (tDCS)</title>
            <description>13 subjects total. 2mA stimulation for 20 minutes.
tDCS</description>
          </group>
          <group group_id="O2">
            <title>Sham Stimulation</title>
            <description>13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
Sham stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Auditory Hallucination Rating Scale (AHRS)Score From Baseline to Day 5</title>
          <description>Examining AHRS total score after 5 days of stimulation compared to baseline assessment total.</description>
          <population>Per protocol; All participants who completed every session of the study from the initial session through the one month follow-up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.38" spread="6.38"/>
                    <measurement group_id="O2" value="-8.54" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there is no difference between the changes in the AHRS score from baseline to 5 days between the groups:
H0: μ1 = μ2 μ1: mean(difference 5 days-baseline) for tDCS group (n=13) μ2: mean(difference 5 days-baseline) for sham group (n=13)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>There was no adjustment because we just performed one comparison</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Difference from Day 5 to Baseline was compared between the sham and the tDCS group using an unpaired t-test. Degrees of freedom: df = 24</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of Decrease in AHRS Score Over Time</title>
        <description>We will re-assess patients one month after the completion of stimulation to evaluate whether their change from baseline to day 5 score on the AHRS persisted over time, namely 30 days.</description>
        <time_frame>Day 5, One month</time_frame>
        <population>Per protocol; All participants who completed every session of the study from the initial session through the one month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Direct Current Stimulation (tDCS)</title>
            <description>13 subjects total. 2mA stimulation for 20 minutes.
tDCS</description>
          </group>
          <group group_id="O2">
            <title>Sham Stimulation</title>
            <description>13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
Sham stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of Decrease in AHRS Score Over Time</title>
          <description>We will re-assess patients one month after the completion of stimulation to evaluate whether their change from baseline to day 5 score on the AHRS persisted over time, namely 30 days.</description>
          <population>Per protocol; All participants who completed every session of the study from the initial session through the one month follow-up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.38" spread="9.06"/>
                    <measurement group_id="O2" value="-4.77" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there is no difference between the AHRS score changes from baseline to 1month between the groups:
H0: μ1 = μ2 μ1: mean(difference 1 month-baseline) for tDCS group (n=13) μ2: mean(difference 1 month-baseline) for sham group (n=13)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>There was no adjustment because we just performed one comparison</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Difference from 1 Month to Baseline was compared between the sham and the tDCS group using an unpaired t-test. Degrees of freedom: df = 24</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collected from the beginning of the study (4/2014) through the completion of the study (10/2014) for a total of 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Transcranial Direct Current Stimulation (tDCS)</title>
          <description>13 subjects total. 2mA stimulation for 20 minutes.
tDCS</description>
        </group>
        <group group_id="E2">
          <title>Sham Stimulation</title>
          <description>13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
Sham stimulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Flavio Frohlich</name_or_title>
      <organization>UNC Chapel Hill</organization>
      <phone>(919) 966-4584</phone>
      <email>flavio_frohlich@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

